Latest Breaking News On - Neurovascular diseases - Page 1 : comparemela.com

Central Nervous System Therapeutics Market to Reach $199.09 Billion, Globally By 2033

Rise in prevalence of neurological conditions, rise in awareness and diagnosis of CNS disorders, surge in research and development by key players, and technological advancements in drug delivery are expected to provide lucrative opportunities for the growth of the market during the forecast period.Wilmington, New Castle, Delaware, Feb. 23, 2024 (GLOBE NEWSWIRE) Allied Market Research published a report, titled, “Central Nervous System (CNS) Therapeutics Market by Disease Type (Neurovascular D

Kidney Dysfunction Is Strongest Death Risk Factor Following Stroke Thrombolysis

Nearly 1 in 3 patients who underwent stroke thrombolysis in this study had stage 3 or higher chronic kidney disease. Kidney dysfunction appears to be a crucial determinant of death risk among patients with stroke thrombolysis.

Kidney disease linked to increased mortality after stroke thrombolysis

Global Embolic Protection Devices Market Gearing Up for Outstanding Expansion at a CAGR of 7.5% During the Forecast Period (2023-28) | Sirtex Medical (LAVA Liquid Embolic System), Abbott, Boston Scientific Corporation, Contego Medical, Cordis, Emboline, InspireMD, Integer Holdings Corporation, Keystone Heart, Medtronic |

Insights on the Central Nervous System Therapeutic Global Market to 2027 - Ongoing Collaborations Am

DUBLIN (BUSINESS WIRE) The "Global Central Nervous System Therapeutic Market (2022-2027) by Disease, Drug Class, Geography, Competitive Analysis, and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.The Global Central Nervous System Therapeutic Market is estim.